Literature DB >> 2859523

Prolongation of the disease-free interval in surgically treated rectal carcinoma.

.   

Abstract

To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients). Five years after the entry of the last patient and with a median follow-up of all survivors for 80 months, the recurrence rate was highest among the control patients (55 per cent) and lowest among the patients receiving a combination of adjuvant radiation and chemotherapy (33 per cent). Time to tumor recurrence differed significantly among the four treatment groups (P less than 0.04); it was significantly prolonged by combined radiation and chemotherapy as compared with resection alone (P less than 0.009). Overall survival did not differ significantly among the treatment groups. The superiority of the combined-modality regimen appeared to be attributable to the effects of radiation therapy and chemotherapy in controlling local and distant recurrences, respectively. We conclude that this study provides evidence supporting the use of postoperative radiation therapy in conjunction with chemotherapy in patients who have had "curative" resection of rectal cancer with involvement of perirectal fat or regional nodes or both (Stages B2 and C).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859523     DOI: 10.1056/NEJM198506063122301

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  181 in total

Review 1.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

Review 2.  Adjuvant therapy for pancreatic adenocarcinoma.

Authors:  R A Abrams
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

Review 3.  Nodal staging of colorectal carcinomas and sentinel nodes.

Authors:  G Cserni
Journal:  J Clin Pathol       Date:  2003-05       Impact factor: 3.411

4.  Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.

Authors:  Ross A Abrams; Kathryn A Winter; William F Regine; Howard Safran; John P Hoffman; Robert Lustig; Andre A Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-02-01       Impact factor: 7.038

5.  Transanal endoscopic microsurgery for rectal cancer. Long-term oncologic results.

Authors:  Jose M Ramirez; Vicente Aguilella; Javier Valencia; Javier Ortego; Jose A Gracia; Pilar Escudero; Ricardo Esco; Mariano Martinez
Journal:  Int J Colorectal Dis       Date:  2011-01-27       Impact factor: 2.571

6.  Chemotherapy of Colorectal Cancer.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  1999-02

7.  Evaluating toxicity in neoadjuvant radio-chemotherapy of rectal cancer.

Authors:  Stefan Höcht
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

8.  [Principles of postoperative therapy in rectal carcinoma].

Authors:  G Folprecht; C-H Köhne
Journal:  Chirurg       Date:  2004-01       Impact factor: 0.955

Review 9.  Management of rectal cancer.

Authors:  James S Wu; Victor W Fazio
Journal:  J Gastrointest Surg       Date:  2004-02       Impact factor: 3.452

Review 10.  Rectal cancer treatment: improving the picture.

Authors:  Juan A Diaz-Gonzalez; Leire Arbea; Javier Aristu
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.